Cargando…
Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
BACKGROUND: Despite the recent improvements in multimodal therapies for oesophageal squamous cell carcinoma (ESCC), the prognosis remains poor. The identification of suitable biomarkers for predicting the prognosis and chemo-sensitivity is required to develop targeted treatments and improve treatmen...
Autores principales: | Hara, Hisashi, Takahashi, Tsuyoshi, Serada, Satoshi, Fujimoto, Minoru, Ohkawara, Tomoharu, Nakatsuka, Rie, Harada, Emi, Nishigaki, Takahiko, Takahashi, Yusuke, Nojima, Satoshi, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Yamasaki, Makoto, Miyata, Hiroshi, Nakajima, Kiyokazu, Takiguchi, Shuji, Morii, Eiichi, Mori, Masaki, Doki, Yuichiro, Naka, Tetsuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931380/ https://www.ncbi.nlm.nih.gov/pubmed/27310703 http://dx.doi.org/10.1038/bjc.2016.183 |
Ejemplares similares
-
Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma
por: Harada, Emi, et al.
Publicado: (2017) -
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
por: Nishigaki, Takahiko, et al.
Publicado: (2020) -
Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma
por: Yaguchi, Tomonori, et al.
Publicado: (2015) -
Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
por: Sugase, Takahito, et al.
Publicado: (2018) -
Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer
por: Sugase, Takahito, et al.
Publicado: (2021)